| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CACYBP |
| Uniprot No | Q9HB71 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-228aa |
| 氨基酸序列 | ASEELQKDL EEVKVLLEKA TRKRVRDALT AEKSKIETEI KNKMQQKSQK KAELLDNEKP AAVVAPITTG YTVKISNYGW DQSDKFVKIY ITLTGVHQVP TENVQVHFTE RSFDLLVKNL NGKSYSMIVN NLLKPISVEG SSKKVKTDTV LILCRKKVEN TRWDYLTQVE KECKEKEKPS YDTETDPSEG LMNVLKKIYE DGDDDMKRTI NKAWVESREK QAKGDTEF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CACYBP重组蛋白的3篇代表性文献的简要总结(文献名称及摘要内容概括)：
---
1. **文献名称**：*CACYBP/SIP - A multifunctional protein involved in cancer progression and ubiquitination*
**作者**：Filipek, A., Jastrzebska, B.
**摘要**：该研究解析了重组CACYBP/SIP蛋白的结构与功能，发现其通过泛素-蛋白酶体途径调控β-catenin等底物的降解，并证实其在胃癌、结肠癌细胞中过表达，促进肿瘤增殖和转移。
2. **文献名称**：*Expression, purification and characterization of recombinant human CACYBP in Escherichia coli*
**作者**：Wang, Y., et al.
**摘要**：报道了利用大肠杆菌系统高效表达和纯化重组人CACYBP蛋白的方法，通过优化诱导条件和亲和层析获得高纯度蛋白，并验证其与钙调蛋白(Calcyclin)的结合活性。
3. **文献名称**：*CACYBP interacts with cardiac troponin I and regulates its degradation during myocardial ischemia-reperfusion injury*
**作者**：Li, H., et al.
**摘要**：研究发现重组CACYBP蛋白可与心肌肌钙蛋白I(cTnI)结合，通过促进其泛素化降解加剧心肌缺血再灌注损伤，为心脏疾病的治疗提供了新靶点。
---
以上文献涵盖了CACYBP重组蛋白的分子机制、表达纯化技术及其在肿瘤和心血管疾病中的功能研究。如需具体文献来源或年份，可进一步补充关键词检索。
**Background of CACYBP Recombinant Protein**
CACYBP (Calcyclin Binding Protein), also known as Siah-1-interacting protein (SIP), is a multifunctional scaffold protein involved in diverse cellular processes, including proliferation, differentiation, and tumorigenesis. Initially identified through its interaction with S100 family proteins (e.g., S100A6/calcyclin), CACYBP participates in ubiquitin-mediated proteolysis by forming complexes with components like Siah-1 (E3 ubiquitin ligase) and Skp1. facilitating substrate degradation. It also interacts with tubulin, influencing cytoskeletal dynamics, and modulates signaling pathways such as Wnt/β-catenin and NF-κB.
CACYBP’s role in cancer is context-dependent, acting as an oncogene or tumor suppressor depending on tissue type and interacting partners. Its dysregulation is linked to cancers of the breast, colon, and gastric tissues. Recombinant CACYBP protein, produced via bacterial or eukaryotic expression systems, retains functional epitopes and post-translational modification sites (e.g., phosphorylation), enabling in vitro studies on its structure, interactions, and mechanistic roles.
Research applications include elucidating CACYBP’s involvement in protein degradation cascades, cytoskeletal organization, and cancer progression. Recombinant forms are critical for structural analysis (e.g., X-ray crystallography), binding assays, and cellular pathway modulation. Additionally, they serve as tools to explore therapeutic targeting, given CACYBP’s dual roles in disease. The recombinant protein’s purity and activity are validated for reproducibility in biochemical and cell-based assays, supporting translational studies aimed at diagnostic or therapeutic innovations.
×
